Glimaday 1 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 1 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, acts by stimulating pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake and utilization. The combination provides complementary mechanisms to achieve better glycemic control in patients inadequately controlled on diet and exercise alone or monotherapy. Glimaday 1 Tablet PR is typically prescribed as part of a comprehensive diabetes management plan including diet, exercise, and regular monitoring of blood glucose. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and rarely hypoglycemia due to glimepiride. Dose adjustments and monitoring of renal function are essential to minimize risks, particularly lactic acidosis associated with metformin. This combination therapy offers an effective option for improving glycemic control with the convenience of a single tablet.